Coherus-Final OS Toripalimab Figure 2 ASCO 2023
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
June 05, 2023 17:30 ET | Coherus BioSciences, Inc.
– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved for NPC in...
7 Hills Logo.png
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
May 22, 2023 13:05 ET | 7 Hills Pharma
HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...
invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023
April 18, 2023 09:00 ET | invIOs GmbH
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver...
invIOs to present at Biotech Showcase
December 14, 2022 08:00 ET | invIOs GmbH
VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter...
7 Hills Logo.png
7 Hills Pharma Expands Pioneering Patent Portfolio With New Claims Covering Innovative Combination Therapies
June 09, 2022 19:53 ET | 7 Hills Pharma
HOUSTON, June 09, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) has secured newly issued US patent claims that significantly expand the extent of the company’s intellectual...
7 Hills Logo.png
New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors
May 18, 2022 19:23 ET | 7 Hills Pharma
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), together with The University of Texas MD Anderson Cancer Center (“MD Anderson”) and Texas Heart Institute (“THI”),...
Logo iOmx.JPG
iOmx to Present New Pre-Clinical Data on SIK3 Checkpoint Inhibitor OMX-0407 at AACR 2022
April 07, 2022 04:00 ET | iOmx Therapeutics AG
MARTINSRIED / MUNICH, Germany, April 07, 2022 (GLOBE NEWSWIRE) -- iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint...
Coherus BioSciences, Inc. logo
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
March 15, 2022 07:30 ET | Coherus BioSciences, Inc.
– Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared to chemotherapy alone – - Data support the use...
Coherus BioSciences, Inc. logo
Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
January 10, 2022 07:30 ET | Coherus BioSciences, Inc.
•  Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combinationin clinical trials in multiple tumor types •  Combinations of PD-1 + TIGIT inhibitors have potential to expand...
Catalym logo.jpg.png
CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
May 20, 2021 03:30 ET | CatalYm GmbH
MUNICH, Germany, May 20, 2021 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that their abstract with first interim data from...